Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to LXRX. [ FAQ on what and how to ask] For non-LXRX questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, United States, 77381
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
CEO & Director
Senior VP & CFO
Senior VP, General Counsel & Secretary
Senior Vice President of Human Resources
Senior VP & Chief Medical Officer
Vice President of Finance & Accounting
Senior Vice President of Investor Relations & Corporate Communications
Senior Vice President of Discovery
Senior VP & Chief Commercial Officer
My Watchlist
